NCT06557291View on ClinicalTrials.gov

Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV Melanoma

CompletedOBSERVATIONAL
Enrollment

38

Participants

Timeline

Start Date

October 4, 2022

Primary Completion Date

November 16, 2023

Study Completion Date

November 16, 2023

Conditions
BRAF V600 Mutated-Stage III/IV Melanoma
Trial Locations (1)

07936

Novartis Pharmaceuticals, East Hanover

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY